These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 30165638)

  • 1. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease.
    Al-Bawardy B; Ramos GP; Willrich MAV; Jenkins SM; Park SH; Aniwan S; Schoenoff SA; Bruining DH; Papadakis KA; Raffals L; Tremaine WJ; Loftus EV
    Inflamm Bowel Dis; 2019 Feb; 25(3):580-586. PubMed ID: 30165638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
    Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
    J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.
    Liefferinckx C; Minsart C; Cremer A; Amininejad L; Tafciu V; Quertinmont E; Tops S; Devière J; Gils A; van Gossum A; Franchimont D
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):478-485. PubMed ID: 30672828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.
    Dreesen E; Verstockt B; Bian S; de Bruyn M; Compernolle G; Tops S; Noman M; Van Assche G; Ferrante M; Gils A; Vermeire S
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1937-1946.e8. PubMed ID: 29704680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
    Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T
    Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939
    [No Abstract]   [Full Text] [Related]  

  • 6. Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.
    Yarur AJ; Deepak P; Vande Casteele N; Battat R; Jain A; Okada L; Osterman M; Regueiro M
    Dig Dis Sci; 2021 Oct; 66(10):3563-3569. PubMed ID: 33089483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
    Singh S; Dulai PS; Vande Casteele N; Battat R; Fumery M; Boland BS; Sandborn WJ
    Aliment Pharmacol Ther; 2019 Oct; 50(8):848-857. PubMed ID: 31483522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
    Ungaro RC; Yarur A; Jossen J; Phan BL; Chefitz E; Sehgal P; Kamal K; Bruss A; Beniwal-Patel P; Fox C; Patel A; Bahur B; Jain A; Stein D; Naik S; Dubinsky MC
    J Crohns Colitis; 2019 Aug; 13(8):963-969. PubMed ID: 31087100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
    J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
    Yacoub W; Williet N; Pouillon L; Di-Bernado T; De Carvalho Bittencourt M; Nancey S; Lopez A; Paul S; Zallot C; Roblin X; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2018 Apr; 47(7):906-912. PubMed ID: 29384209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.
    Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R
    Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis.
    Noman M; Ferrante M; Bisschops R; De Hertogh G; Van den Broeck K; Rans K; Rutgeerts P; Vermeire S; Van Assche G
    J Crohns Colitis; 2017 Sep; 11(9):1085-1089. PubMed ID: 28369329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort.
    Buer LCT; Moum BA; Cvancarova M; Warren DJ; Bolstad N; Medhus AW; Høivik ML
    Scand J Gastroenterol; 2019 Jan; 54(1):41-48. PubMed ID: 30650312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
    Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease.
    Jossen J; Kiernan BD; Pittman N; Dubinsky MC
    J Pediatr Gastroenterol Nutr; 2020 Mar; 70(3):304-309. PubMed ID: 31738290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease.
    Guidi L; Pugliese D; Panici Tonucci T; Bertani L; Costa F; Privitera G; Tolusso B; Di Mario C; Albano E; Tapete G; Gremese E; Papa A; Gasbarrini A; Rapaccini GL; Armuzzi A
    United European Gastroenterol J; 2019 Nov; 7(9):1189-1197. PubMed ID: 31700632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.